Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles

Northwest Women's and Children's Hospital, Xi'an, Shaanxi0 sites400 target enrollmentSeptember 2016

ConditionsGnRHa;LPS

InterventionsGonadotrophin releasing hormone agonist(GnRHa)

DrugsGonadotrophin releasing hormone agonist(GnRHa)

Overview

Phase: Phase 1
Intervention: Gonadotrophin releasing hormone agonist(GnRHa)
Conditions: GnRHa;LPS
Sponsor: Northwest Women's and Children's Hospital, Xi'an, Shaanxi
Enrollment: 400
Primary Endpoint: pregnancy rate
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The study was designed to investigate the effect of luteal-phase administration of gonadotrophin releasing hormone agonist(GnRHa) on pregnancy outcomes in in-vitro fertilization-embryo transfer.

Registry

clinicaltrials.gov

Start Date

September 2016

End Date

September 2017

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Northwest Women's and Children's Hospital, Xi'an, Shaanxi

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age \< 37 years;
•One or more high quality embryos have been got in IVF/ICSI treatment;
•To transfer at lest 2 fresh embryos;
•Uterine endometrial thickness ≥ 7mm;
•Patients have signed informed consents.

Exclusion Criteria

•≥3 IVF/ICSI/FET cycles and no pregnancy;
•Polycystic ovary syndrome(PCOS);
•uterine malformation;
•endometriosis
•patients with a history of recurrent pregnancy loss.

Arms & Interventions

GnRHa group

Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.

Intervention: Gonadotrophin releasing hormone agonist(GnRHa)